Moderna, $MRNA , is now up more than 600% this year.
It started 2026 at about $29, now at $225.
It’s one of the best-performing stock in the S&P 500.
The run:
August: jumped 140% in a single day on positive late-stage melanoma vaccine data
September: kept climbing toward $200
On Oct 9: up 14% after reports the NIH will push to speed up personalized cancer vaccines
It started 2026 at about $29, now at $225.
It’s one of the best-performing stock in the S&P 500.
The run:
August: jumped 140% in a single day on positive late-stage melanoma vaccine data
September: kept climbing toward $200
On Oct 9: up 14% after reports the NIH will push to speed up personalized cancer vaccines